{"analyses":[{"ciLowerLimit":"-6.925","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"45.386","groupDescription":"Percentage of Participants With RBCs-transfusion Independence","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.162","pValueComment":"P-value is from an unstratified Cochran-Mantel Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"19.231","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-26.381","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"66.381","groupDescription":"Percentage of Participants With Platelet-transfusion Independence","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.454","pValueComment":"P-value is from an unstratified Cochran-Mantel Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"20.000","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"69.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"RBCs-transfusion Independence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0"},{"groupId":"OG001","value":"80.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Platelet-transfusion Independence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized. Overall number analyzed are the number of participants from a subset of the ITT Population who were transfusion dependent at Baseline. Number analyzed is the number of participants who were transfusion dependent at Baseline for the specified category.","reportingStatus":"POSTED","timeFrame":"8 weeks before randomization through 30 days after last dose of any study drug (up to approximately 5 years and 3 months)","title":"Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence","type":"SECONDARY","unitOfMeasure":"percentage of participants"}